Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Equazen Pro
- Development stage
- Unknown
- Lead developer
- SFI Health
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Equazen Pro is a medical food developed by SFI Health (formerly associated with Vifor Pharma) containing a clinically researched 9:3:1 ratio of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and gamma-linolenic acid (GLA). It is specifically formulated for the nutritional management of attention-deficit/hyperactivity disorder (ADHD), developmental coordination disorder, and learning difficulties in children and adolescents. The product works by addressing polyunsaturated fatty acid deficiencies common in individuals with ADHD. These essential fatty acids are incorporated into neuronal cell membranes, where they modify phospholipid composition and influence membrane fluidity. This modulation affects the function of membrane-bound proteins, including dopamine and serotonin transporters, supports brain cell signaling, and modulates inflammatory pathways via receptors such as free fatty acid receptor 4 (FFAR4).
- Brand names
- Equazen ProEquazenEye Q
- Other names
- EPA + DHA + GLA 9:3:1 ratioOmega-3/6 supplement
02
Targets
DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)FFAR4 (Free fatty acid receptor 4)
Beyond the preview
Go deeper on Equazen Pro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Equazen Pro.